Chromogranin A (CgA), a neuroendocrine pro-hormone, is proteolytically cleaved into bioactive peptides, most notably catestatin (CST) and pancreastatin (PST), which exert opposing effects on metabolic and inflammatory processes. Using CgA- and CST knockout (KO) mice, we investigated the roles of these peptides in pancreatic endocrine function, morphology, neurotransmitter dynamics, and systemic glucose homeostasis. CST-KO mice displayed impaired insulin secretion in vivo (but not ex vivo), disrupted islet architecture, and elevated catecholamine levels. In contrast, CgA-KO mice, which lack both CST and PST, exhibited reduced beta-cell mass but improved insulin sensitivity due to absence of PST. Peptide supplementation experiments in CgA-KO mice revealed that CST suppressed gluconeogenesis and enhanced glucagon regulation, whereas PST promoted insulin resistance and glucose production. Spatial mass spectrometry further demonstrated altered neurotransmitter and polyamine profiles in KO islets, implicating disrupted nerve-immune-islet crosstalk as a contributor to the observed metabolic phenotypes. Collectively, these findings identify CgA-derived peptides as critical regulators of islet function and highlight CST as a promising therapeutic candidate for diabetes and metabolic-inflammatory disorders.
Chromogranin A (CgA), a 439–amino acid–long protein produced by neuroendocrine cells, is critical in health and disease. Through proteolytic processing, CgA is transformed into several bioactive peptides. These peptides, as well as CgA, have been implicated in various pathological conditions. Interestingly, CgA-derived peptides have opposing effects, such as catestatin (CST) and pancreastatin (PST), which have contrasting immunomodulatory properties. PST promotes a proinflammatory response, increasing the production of proinflammatory cytokines, whereas CST reduces proinflammatory and increases anti-inflammatory cytokines in mice. However, how CgA and CgA-derived peptides regulate the immune response is unknown, and most of our knowledge is based on mouse studies. Since multiple studies suggest that CgA and CgA-derived peptides influence macrophages, we aimed to investigate the interaction between CgA and human monocyte-derived macrophages. Therefore, we tested whether human macrophages produce CgA, are affected by CST and PST, and/or produce CST and PST. We found that human monocyte-derived macrophages and other immune cells do not produce CgA, and CST and PST have only minor effects on cytokine production and immune metabolism. However, proteases involved in the cleavage of CgA are differentially expressed in macrophages depending on their inflammatory phenotype, suggesting that CgA is increasingly converted into CST and PST in inflammatory conditions. As levels of CgA and its cleavage products CST and PST are associated with human diseases, it is essential to understand how they influence the immune response.
Background The pro-hormone chromogranin A (CgA) and its bioactive cleavage product catestatin (CST) are both associated with inflammatory bowel disease (IBD) and dysregulated barrier functions, but their exact role has remained elusive. Here, we demonstrate that CST regulates the colonic mucus layer. Methods CST levels were measured in feces of IBD patients. The mucus layer, goblet cells, and immune cell infiltration were analyzed by histology and electron microscopy in colon tissue from IBD patients and mice with selective deletion of the CST-coding region of the CgA gene. Results CST levels were elevated in feces of IBD patients compared to healthy controls. The thickness of the mucus layer was increased in non-affected, but not in inflamed, regions of the colon in IBD patients. The thickness of the mucus layer and concomitant mucus production were also increased in the CST-KO mouse. This mucus phenotype in CST-KO mice could be reversed by bone marrow transplantation from wildtype mice. Conclusions CST produced by bone-marrow derived immune cells reduces production of the mucus layer in the intestine. This might contribute to the reduced mucus layer in inflamed colon regions of IBD patients. Additionally, CST feces levels might be a biomarker for IBD.
Increased levels of the anti-inflammatory peptide catestatin (CST), a cleavage product of the pro-hormone chromogranin A, correlates with less severe outcomes in hypertension, colitis and diabetes. However, it is unknown how CST reduces the infiltration of monocytes and macrophages in inflamed tissues. Here, we report that CST blocks leukocyte migration towards inflammatory chemokines. By in vitro and in vivo migration assays, we show that although CST itself is weakly chemotactic, it blocks migration of monocytes and granulocytes to inflammatory attracting factor CC-chemokine ligand 2 (CCL2) and macrophage inflammatory protein 2 (MIP-2). Moreover, it directs CX 3 CR1 + macrophages away from pancreatic islets. These findings support the emerging notion that CST is a key anti-inflammatory modulator.
Interleukin-12 (IL-12) is a key immunostimulatory cytokine produced by dendritic cells (DCs) upon infection that plays a central role in the activation and differentiation of cytotoxic T cells. Notably, IL-12 is secreted in a highly polarized manner from late endosomes or lysosomes at the contact interface between a DC and a T cell, known as the immunological synapse. However, the signaling mechanisms initiating this spatially restricted cytokine release remain poorly defined. Here, using artificial T cell mimics, beads coated with T cell surface ligands, we show that antigen recognition induces recruitment of the DC’s microtubule organizing center (MTOC) and Golgi apparatus to the immunological synapse via reverse MHC class I signaling. Our results further indicate that the signaling pathways governing MTOC polarization are highly conserved in DCs, consistent with mechanisms described in other immune cell types. As newly synthesized IL-12 traffics through the Golgi, this intracellular reorientation facilitates localized release of IL-12 directly at the site of T cell engagement, likely enabling DCs to focus their stimulatory capacity on responsive T cells within the crowded environment of secondary lymphoid organs. Furthermore, by applying spatially patterned antibody arrays targeting MHC class I, we reveal that MTOC polarization is biased toward sites exhibiting the strongest reverse MHC class I signaling. This suggests that IL-12 is preferentially released at synapses formed with T cells displaying higher T cell receptor affinity, providing a mechanism for selection of the most potent T cell.
Chromogranin A (CgA), a neuroendocrine pro-hormone, undergoes proteolytic cleavage to yield bioactive peptides, notably catestatin (CST) and pancreastatin (PST), which exert opposing effects on metabolic and inflammatory processes. Using CgA and CST knockout (KO) mice, this study investigated their roles in pancreatic endocrine function, morphology, neurotransmitter dynamics, and systemic glucose homeostasis. CST deficiency induced insulin resistance, altered islet architecture, and heightened catecholamine levels, whereas CgA-KO mice lacking both CST and PST exhibited improved insulin sensitivity due to absence of PST. CST suppressed gluconeogenesis and enhanced glucagon regulation, while PST promoted insulin resistance and glucose production. Spatial mass spectrometry revealed altered neurotransmitter and polyamine profiles in pancreatic islets, implicating disrupted nerve-immune-islet interactions. CST’s modulation of catecholaminergic and inflammatory pathways positions it as a key regulator in the neuro-immune-endocrine axis. These findings highlight the therapeutic potential of targeting CgA-derived peptides, especially CST, for managing diabetes and metabolic-inflammatory diseases through precise peptide-based interventions.